CLINICAL TRIALS PROFILE FOR AVIBACTAM SODIUM; CEFTAZIDIME
✉ Email this page to a colleague
All Clinical Trials for AVIBACTAM SODIUM; CEFTAZIDIME
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT06650384 ↗ | Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity | RECRUITING | Ain Shams University | PHASE2 | 2024-11-01 | Healthcare- associated infections that caused by multi-drug-resistant Gram-negative bacteria (MDR G-ve) represent the most important problem that face the critically ill patients in the ICU. The available broad-spectrum antibiotics as penicillin, fluoroquinolones, aminoglycosides, and -lactams fail to overcome these aggressive organisms. Accordingly, this led to the reconsideration of old drugs such as polymyxin B and polymyxin E (also known as colistin) that were previously considered to be too toxic for clinical use in the treatment of MDR G-ve bacteria. Colistin can be used as monotherapy or in combination with other antibiotics as high dose tigecycline, carbapenem or high-dose ampicillin/sulbactam. Colistin associated acute kidney injury (CA-AKI) is the frequently observed side effect in ICU patients treated with colistin that may lead to cessation of treatment. Accordingly, it is important to monitor renal functions prior to and during colistin treatment to detect the early signs of renal injury and minimize long term renal dysfunction. Inflammation with release of reactive oxygen species (ROS) can lead to renal tubular cells apoptosis. Several animal studies proved the beneficial effect of the concomitant use of antioxidants as N-acetylcysteine, alpha lipoic acid in preventing or attenuating colistin induced nephrotoxicity by their potent antioxidant effects Therefore, a clinical trial will be carried out to evaluate the efficacy and safety of N-acetylcysteine versus Alpha-lipoic acid in the prevention of colistin-induced nephrotoxicity in critically ill patients. |
| NCT07327619 ↗ | A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP | NOT_YET_RECRUITING | Qilu Pharmaceutical Co., Ltd. | PHASE3 | 2026-04-01 | This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and Avibactam Sodium for Injection. This study is a randomized, double-blind, active-controlled study. The total duration of the study will be approximately 32 days including screening and follow-up. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AVIBACTAM SODIUM; CEFTAZIDIME
Condition Name
Clinical Trial Locations for AVIBACTAM SODIUM; CEFTAZIDIME
Clinical Trial Progress for AVIBACTAM SODIUM; CEFTAZIDIME
Clinical Trial Phase
Clinical Trial Sponsors for AVIBACTAM SODIUM; CEFTAZIDIME
Sponsor Name
